Aim immunotech submits pre-ind application to the fda for phase 2 clinical study of ampligen as a potential infusion therapy for post-covid-19 cognitive dysfunction

Ocala, fla., sept. 08, 2021 (globe newswire) -- aim immunotech inc. (nyse american: aim) today announced that is has submitted a pre-investigational new drug application (pre-ind) to the u.s. food and drug administration (fda) for a phase 2 clinical study of ampligen as a potential infusion therapy for post-covid-19 cognitive dysfunction (pccd).
AIM Ratings Summary
AIM Quant Ranking